SAN DIEGO, CA -- (Marketwired) -- 02/18/14 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is pleased to announce that three of the Company's innovative products were named on the "100 Minimally Invasive Orthopedic & Spine Devices to Know" list. The list highlights devices and instruments used in minimally invasive orthopedic procedures, including knee, hip, shoulder, extremities, and spine surgery.
The list named recently-launched products including ALIF ACR (Anterior Lumbar Interbody Fusion - Anterior Column Realignment) and the XLIF Decade Plate as well as CoRoent® XL, all unique solutions designed to improve the patient and physician experience.
The hyperlordotic implants developed for the ALIF ACR procedure represent the Company's latest innovative advancement in an effort to improve sagittal plane deformity correction. The XLIF Decade Plate was designed to enable single approach lateral surgery. It incorporates the Company's ten years of XLIF® experience into a fixation system built upon the latest technologies, while offering uncompromised biomechanical characteristics. Lastly, the CoRoent XL implant has one of the largest footprints available to intervertebral spinal fusion patients.
"I am exceptionally pleased that several of our latest innovations have been recognized for innovating minimally invasive spine procedures," said Pat Miles, President of Global Products and Services. "NuVasive is driving the global conversion toward minimally invasive solutions in spine, and these products are great examples of how we are driving that shift; using innovation to change spine surgery. I can't wait to see how our unrivaled decade of experience pioneering the lateral solution will continue to improve patient outcomes in the years to come."
About Becker's ASC Review
Becker's ASC Review is a Chicago-based publication focused on providing the most relevant business and legal news and analysis for ambulatory surgery center owners, operators, administrators, and decision-makers. The publication includes weekly electronic newsletters, extra online content and bi-monthly print publications sent to ASC leaders across the country.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.